Payment overview · 2025
General Payments
$345.09
20 reported records · 10 companies
Healthcare provider profile · identity verified
David G Fagan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VALLEY, AL · NPI 1912929068
Verified facts
What the public records show
CMS Open Payments records show David G Fagan, M.D. received $345.09 in general payments during 2025 across 20 reported records.
GlaxoSmithKline, LLC. accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 288 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.37 | 17.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.92 | 16.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.96 | 12.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.51 | 11.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.26 | 11.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.26 | 9.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.24 | 7.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.85 | 4.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.81 | 4.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.91 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $345.09 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.73 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.96 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.24 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 16 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 164 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 151 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
151 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
288 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 729 | 197 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 646 | 193 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 642 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 160 |
| Gabapentin | Gabapentin | 534 | 123 |
| Lisinopril | Lisinopril | 521 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 426 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 353 | 108 |
| Metformin Hcl | Metformin Hcl | 342 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 341 | 100 |
| Carvedilol | Carvedilol | 340 | 97 |
| Tramadol Hcl | Tramadol Hcl | 327 | 57 |
| Losartan Potassium | Losartan Potassium | 321 | 98 |
| Omeprazole | Omeprazole | 317 | 93 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 309 | 93 |
| Famotidine | Famotidine | 308 | 90 |
| Clonazepam | Clonazepam | 302 | 52 |
| Eliquis | Apixaban | 288 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 269 | 88 |
| Simvastatin | Simvastatin | 264 | 74 |
| Meloxicam | Meloxicam | 262 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 259 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 250 | 75 |
| Furosemide | Furosemide | 240 | 75 |
| Potassium Chloride | Potassium Chloride | 240 | 66 |
| Sertraline Hcl | Sertraline Hcl | 225 | 60 |
| Alprazolam | Alprazolam | 216 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 189 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 67 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 169 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 168 | 26 |
| Jardiance | Empagliflozin | 164 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 151 | 28 |
| Prednisone | Prednisone | 137 | 60 |
| Trazodone Hcl | Trazodone Hcl | 137 | 38 |
| Mirtazapine | Mirtazapine | 135 | 40 |
| Allopurinol | Allopurinol | 125 | 36 |
| Bupropion Xl | Bupropion Hcl | 119 | 31 |
| Lorazepam | Lorazepam | 119 | 25 |
| Donepezil Hcl | Donepezil Hcl | 113 | 25 |
| Ozempic | Semaglutide | 106 | 15 |
| Pregabalin | Pregabalin | 105 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 104 | 32 |
| Mounjaro | Tirzepatide | 103 | 24 |
| Valsartan | Valsartan | 103 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 29 |
| Celecoxib | Celecoxib | 95 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 40 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 88 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 19 |
| Montelukast Sodium | Montelukast Sodium | 79 | 25 |
| Farxiga | Dapagliflozin Propanediol | 78 | 20 |
| Enalapril Maleate | Enalapril Maleate | 76 | 19 |
| Memantine Hcl | Memantine Hcl | 76 | 15 |
| Spironolactone | Spironolactone | 72 | 22 |
| Glimepiride | Glimepiride | 71 | 26 |
| Metformin Hcl Er | Metformin Hcl | 70 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 24 |
| Propranolol Hcl | Propranolol Hcl | 64 | 12 |
| Colchicine | Colchicine | 62 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 18 |
| Lovastatin | Lovastatin | 56 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 54 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 18 |
| Nifedipine Er | Nifedipine | 53 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 41 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 20 |
| Promethazine Hcl | Promethazine Hcl | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 15 |
| Warfarin Sodium | Warfarin Sodium | 50 | 15 |
| Olanzapine | Olanzapine | 48 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 13 |
| Novolog Flexpen | Insulin Aspart | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 35 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 44 | 35 |
| Ibuprofen | Ibuprofen | 44 | 12 |
| Levetiracetam | Levetiracetam | 44 | 11 |
| Verapamil Er | Verapamil Hcl | 42 | 11 |
| Alendronate Sodium | Alendronate Sodium | 41 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 39 | 15 |
| Estradiol | Estradiol | 38 | 13 |
| Mometasone Furoate | Mometasone Furoate | 38 | 15 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 11 |
| Torsemide | Torsemide | 35 | 14 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Methylprednisolone | Methylprednisolone | 32 | 25 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 23 |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Nystatin | Nystatin | 28 | 14 |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Etodolac | Etodolac | 27 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 21 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Azithromycin | Azithromycin | 16 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $345.09 · 20 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, CAPLYTA, Cologuard Collection Kit, JARDIANCE, NURTEC ODT, NUZYRA, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error